ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,907Medicare Part D Prescriptions Filled, Including Refills

Rank: 84 out of 1290

$607K Total Retail Price of All Prescriptions

Rank: 139 out of 1290

440 Patients Receiving at Least One Drug in Part D
68%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 440 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

17% of this provider’s 440 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

3% of this provider’s 6,055 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $94 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
OMEPRAZOLE 324 242 1 2
LISINOPRIL 283 224 2 5
SIMVASTATIN 282 234 3 1
HYDROCODONE-ACETAMINOPHEN 280 190 S3 4 6
AMLODIPINE BESYLATE 261 220 5 3
LEVOTHYROXINE SODIUM 253 173 6 4
HYDROCHLOROTHIAZIDE 227 177 7 20
LOSARTAN POTASSIUM 174 123 8 19
ZOLPIDEM TARTRATE 167 98 9 15
GABAPENTIN 165 109 10 8
METFORMIN HCL 145 97 11 10
FUROSEMIDE 144 108 12 9
FLUTICASONE PROPIONATE 140 61 13 26
CITALOPRAM HBR 131 97 14 29
CARVEDILOL 122 100 15 12
FENOFIBRATE 116 82 16 98
ATENOLOL 114 96 17 18
ATORVASTATIN CALCIUM 110 66 18 23
LISINOPRIL-HYDROCHLOROTHIAZIDE 107 97 19 92
METOPROLOL SUCCINATE 106 82 20 14
LOSARTAN-HYDROCHLOROTHIAZIDE 100 89 21 106
POTASSIUM CHLORIDE 97 54 22 35
CYCLOBENZAPRINE HCL 90 48 R 23 105
CLONIDINE HCL 88 52 24 66
MELOXICAM 85 74 25 31
NEXIUM 81 38 26 34
CYMBALTA 79 33 27 59
LOVASTATIN 76 58 28 45
SERTRALINE HCL 76 59 28 36
METFORMIN HCL ER 75 55 30 135
SYNTHROID 74 64 31 28
METOPROLOL TARTRATE 70 64 32 7
ESTRADIOL 68 23 R 33 177
FLUOXETINE HCL 66 53 34 79
PRAVASTATIN SODIUM 61 35 35 42
LANTUS SOLOSTAR 61 32 35 88
IBUPROFEN 60 15 37 74
SPIRIVA 59 29 38 75
DOXAZOSIN MESYLATE 58 41 39 64
METHYLPREDNISOLONE 58 45 39 101
TRAMADOL HCL 56 26 41 25
DONEPEZIL HCL 56 49 41 13
AMITRIPTYLINE HCL 53 48 R 43 97
DILTIAZEM 24HR CD 53 52 43 315
TOPIRAMATE 52 11 45 91
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 12, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.